• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

Angiotensin-receptor blockers in diabetic nephropathy [Classics Series]

byAndrew Cheung, MD MBA
August 29, 2013
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Irbesartan was associated with a significantly lower risk of doubling of serum creatinine concentration, developing end-stage renal disease, or death from all causes.

2. Serum creatinine concentration increased at a slower rate in patients receiving irbesartan compared to amlodipine and placebo groups.

Original Date of Publication: September 20, 2001

Study Rundown: The Irbesartan Diabetic Nephropathy Trial assessed the ability of an angiotensin-II-receptor blocker (ARB), irbesartan and a calcium-channel blocker (CCB), amlodipine to protect against renal deterioration in patients with nephropathy due to type 2 diabetes mellitus (T2DM). At the time of this study’s publication, inhibitors of the renin-angiotensin-aldosterone system were known to be effective in patients with nephropathy due to type 1 diabetes but no major trial had investigated these agents in patients with nephropathy due to T2DM. While no significant differences were observed between the amlodipine and placebo treatment groups, irbesartan was associated with a significantly lower relative risk of a composite end point that included doubling of serum creatinine concentration, onset of end-stage renal disease, and death from any cause (P=0.02 for placebo, P=0.006 for amlodipine). Irbesartan was also associated with a slower rate of increase in serum creatinine concentration. These protective effects were found to be independent of the drug’s benefit in lowering blood pressure.

In summary, the ARB, irbesartan has renoprotective effects in addition to lowering blood pressure in patients with nephropathy due to T2DM.

RELATED REPORTS

Oral semaglutide reduces cardiovascular event rates in high-risk patients

Spot capillary HbA1c testing may have a role in early detection of type 2 diabetes

Automated insulin delivery improves glycemic control over continuous glucose monitoring

Please click to read study in NEJM

In-Depth [randomized, controlled study]: Originally published in 2001 in NEJM, this trial randomly assigned 1,715 patients with a documented diagnosis of T2DM and hypertension to one of three treatment arms: 1) the ARB, irbesartan, 2) the CCB, amlodipine, or 3) placebo. The target blood pressure for all patients was the same (135/85 mmHg or less) and blood pressure was managed as needed with antihypertensive agents other than ACE-inhibitors, ARBs, and CCBs. The primary end point was a composite of doubling of baseline serum creatinine concentration, development of end-stage renal disease, or death from any cause. A composite cardiovascular end point was measured as a secondary outcome.

The relative risk of the primary end point was not significantly different between the placebo and amlodipine groups. Patients receiving irbesartan had a 20% lower relative risk of the primary end point than patients in the placebo group (P=0.02) and a 23% lower risk that those in the amlodipine group (P=0.006). There was no significant difference in the occurrence of the composite cardiovascular outcome among the three groups. Serum creatinine concentration increased at significantly slower rates in the irbesartan group than in the placebo and amlodipine groups. Hyperkalemia requiring discontinuation of trial medication occurred more frequently in the irbesartan group than in the placebo and amlodipine groups.

By Adrienne Cheung and Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: arbchronic kidney diseasetype 2 diabetes
Previous Post

The Val-HeFT trial: Valsartan reduces morbidity in chronic heart failure [Classics Series]

Next Post

Terminology used to describe ductal carcinoma in situ impacts patient preferences

RelatedReports

Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients
Cardiology

Oral semaglutide reduces cardiovascular event rates in high-risk patients

June 5, 2025
Food environment associated with gestational diabetes
Chronic Disease

Spot capillary HbA1c testing may have a role in early detection of type 2 diabetes

April 10, 2025
Insulin costs rose exponentially, regardless of formulation or patent
Cardiology

Automated insulin delivery improves glycemic control over continuous glucose monitoring

April 8, 2025
#VisualAbstract: Automated Insulin Delivery Effectively Reduces Blood Glucose Levels in Type 2 Diabetes
StudyGraphics

#VisualAbstract: Automated Insulin Delivery Effectively Reduces Blood Glucose Levels in Type 2 Diabetes

March 31, 2025
Next Post
One-year of Herceptin preferable to two-year regimen

Terminology used to describe ductal carcinoma in situ impacts patient preferences

Fluconazole in first trimester not associated with increase in most birth defects

Fluconazole in first trimester not associated with increase in most birth defects

Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]

Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.